Telomir Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 results for the period ended June 30, 2026, missed consensus on the bottom line with GAAP EPS of -$0.79 vs. -$0.07 expected. The variance was driven by a $46.1M non-cash deemed dividend related to the TELI acquisition, which significantly reduced income available to stockholders. While revenue remained at zero in-line with expectations, R&D expenses jumped to $0.44M as the company prepares to transition Telomir-Zn into clinical trials.